LivaNova PLC Receives Regulatory Approval in Canada for its Innovative Memo 3D ReChord Annuloplasty Ring for Mitral Valve Repair
Incorporating an Innovative Chordal Guiding System, the Memo 3D ReChord Simplifies the Surgical Approach While Providing Physiological Results
LONDON, March 9, 2016 – LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a global medical technology company, today announced the Canadian approval of its Memo 3D ReChord, a semirigid prosthetic annuloplasty ring for Mitral Valve Repair (MVR). As the most frequently performed procedure for mitral valve disease, MVR is an option, rather than mitral valve replacement, that can provide patients with improved heart function and preservation of lifestyle.
The Memo 3D ReChord incorporates an innovative chordal guiding system, allowing mitral chords replacement to be a routine procedure without the need for chordal measurement while enhancing procedural control, delivering reproducible results and accelerating procedure times. Artificial chords implantation through Memo 3D ReChord is a reproducible technique, suitable for both anterior and posterior leaflet prolapse, which restores leaflet motion, ensures a large surface of coaptation and further facilitate a MIMV surgical approach.1
The Memo 3D ReChord features a unique super-elastic alloy core that supports the mitral annulus and facilitates natural, physiologic 3D-motion similar to that of the native mitral annulus. Additionally, the ring features a Carbofilm™ coating to enhance hemo-and biocompatibility. The Memo 3D ReChord is designed to provide reproducible and physiological results, offering a unique and optimal solution across the entire range of MVR procedures.
For further information, please click here: Memo 3D ReChord
1- Glauber et al., Ann Cardiothorac Surg. 2015;4 (3):298-300